Language selection

Search

Patent 1302923 Summary

Third-party information liability

Some of the information on this Web page has been provided by external sources. The Government of Canada is not responsible for the accuracy, reliability or currency of the information supplied by external sources. Users wishing to rely upon this information should consult directly with the source of the information. Content provided by external sources is not subject to official languages, privacy and accessibility requirements.

Claims and Abstract availability

Any discrepancies in the text and image of the Claims and Abstract are due to differing posting times. Text of the Claims and Abstract are posted:

  • At the time the application is open to public inspection;
  • At the time of issue of the patent (grant).
(12) Patent: (11) CA 1302923
(21) Application Number: 1302923
(54) English Title: PROCESS FOR PRODUCING 4-ANDROSTENE -3,17-DIONE AND 1,4-ANDROSTARDIENE -3,17-DIONE
(54) French Title: PROCEDE POUR LA PRODUCTION DE LA 4-ANDROSTENE-3,17-DIONE ET DE LA 1,4-ANDROSTARDIENE-3,17-DIONE
Status: Expired and beyond the Period of Reversal
Bibliographic Data
(51) International Patent Classification (IPC):
  • C12P 33/12 (2006.01)
  • C12P 33/00 (2006.01)
(72) Inventors :
  • WEBER, ALFRED (Germany)
  • KENNECKE, MARIO (Germany)
  • KURZIDIM, JOHANNES (Germany)
(73) Owners :
  • SCHERING AKTIENGESELLSCHAFT
(71) Applicants :
  • SCHERING AKTIENGESELLSCHAFT (Germany)
(74) Agent: MARKS & CLERK
(74) Associate agent:
(45) Issued: 1992-06-09
(22) Filed Date: 1986-12-12
Availability of licence: N/A
Dedicated to the Public: N/A
(25) Language of filing: English

Patent Cooperation Treaty (PCT): No

(30) Application Priority Data:
Application No. Country/Territory Date
P 35 44 662.5 (Germany) 1985-12-13

Abstracts

English Abstract


ABSTRACT OF THE DISCLOSURE
A process for producing 4-androstene-3,17-dione and
1,4-androstadiene-3,17-dione having the general formula
<IMG>
wherein <IMG> symbolizes a single bond or double bond, in which
.alpha.-sitosterol
<IMG>
is fermented with a culture of a microorganism strain capable
of side-chain degradation of sterols.


Claims

Note: Claims are shown in the official language in which they were submitted.


THE EMBODIMENTS OF THE INVENTION IN WHICH AN EXCLUSIVE
PROPERTY OR PRIVILEGE IS CLAIMED ARE DEFINED AS FOLLOWS:
1. A process for producing 4-androstene-3,17-dione
and 1,4-androstadiene-3,17-dione having the general formula
<IMG>
wherein <IMG> symbolizes a single bond or a double bond, in
which .alpha.-sitosterol
<IMG>
is fermented with a culture of a microorganism strain capable
of side-chain degradation of sterols.
2. A process according to claim 1 in which the fer-
mentation is effected with a microorgansim of the species
Arthrobacter, Brevibacterium, Microbacterium, Protaminobacter,
Streptomyces or Mycobacterium.
3. A process according to claim 1 in which .alpha.-
sitosterol is fermented with a microorganism strain of the
species Micobacterium or Norcardia which is capable of side-
chain degradation of sterols.
4. A process according to claim 1 in which .alpha.-
sitosterol is fermented with Mycobacterium spec. NRRL B-=3805,
Mycobacterium spec. NRRL B-3683, Microbacterium pheli NRRL B-
8154 or Micobacterium fortuitum NRRL B-8153.

Description

Note: Descriptions are shown in the official language in which they were submitted.


1302923
The present invention relates to a process for pro-
ducing 4-androstene-3,17-dione and 1,4-androstadiene-3,17-
dione.
According to the present invention there is provided
a process for producing 4-androstene-3,17-dione and 1,4-
androstadiene-3,17-dione having the general formula
,~"~~
0~
wherein ' symboIizes a single bond or a double bond, in
which ~-sitosterol ~ I
/C~' ~
110 ~
~l3H
is fermented with a culture of a microorganism strain capable
of side-chain degradation of sterols.
It is known that numerous microorganisms (as for
example, those of the species Arthrobacter, Brevibacterium,
Microbacterium, Protamlnobacter, Bacill~s, Norcardia, Strepto-
myces and particularly Mycobacterium) have the natural capa-
bility of degrading naturally occurring 3 ~ ~hydroxy- ~ 5-
sterols (such as cholesterol or sitosterol) to carbon dioxide
and water and that 4-androstene-3,17-dione and 1,4-andros-
tadiene-3,17-dione are intermediately formed in this degrada-
tion.
It is also known that by adding inhibitors or
mutated microorganisms it~is possible to so control the degra-
dation of the sterols that a degradation of the 4-androstene-
3,17-dione or 1,4-androstadiene-3,17-dione is avoided (see
- 1 - ~k

i;~O29~3
German Offenlegungsschriften 15 43 269 and 15 9~ 327 and ~.S.
Patent 3 684 657).
For a person skilled in the art it is surprising
that under conventional conditions the side-chain of ~ -
sitosterol is also degraded since it is known that the side-
chain degradation of sterols is caused by a very complex
fermentation system and it could not be expected that all the
enzymes cooperating in the side-chain degradation of natural
steroids also have the capability of causing the side-chain
degradation of this compound. Furthermore, it could not be
predicted that in this degradation the ~ 7 double bond of the
~-sitosterol hydrogenates and that the methyl group in the 4
position is split.
Apart from the use of other starting compounds the
process according to the present invention is carried under
the same fermentation conditions as those used in conventional
microbiological side-chain degradation reactions of sterols.
According to the present invention the fermentation
is,carried out by using the microorganisms culture usually
applied for the side-chain degradation of sterols. Suitable
cultures are, for example, bacteria cultures capable of side-
chain degradation of sterols, i.e., of the species Arthrobac-
ter, Brevibacterium, Microbacterium, Protaminobacter, Strepto-
myces or particularly of the species Mycobacterium. The fol-
lowing microorganisms are suitable: Microbacterium lactum IAM-
1640, Protaminobacter alboflavus IAM-1040, Bacillus roseus
IAM-1257, Bacillus spharicus ATTC-7055, Norcardia gardneri
IAM-105, Norcardia minima IAM-374, Norcardia corallina IFO-
3338, Streptomyces rubescens IAM-74 or particularly the
microorganisms Mycobacterium avium IFO-3082, Mycobacterium
pheli IFO-3158, Mycobacterium pheli (Institut fur Gesund-
heitswesen, Budapest No. 29), Mycobacterium pheli ATCC-354,

1302923
Mycobacterium smegmatis IF0-3084, Mycobacterium smegmatis
ATCC-20, Mycobacterium smegmatis (Institut fur Gesundheitswe-
sen, Budapest No. 27), Mycobacterium smegmatis ATCC-19979 and
Mycobacterium fortuitum CBS-49566.
Particularly preferred microorganisms are Mycobac-
terium spec. NRRL B-3805, Mycobacterium spec. B-3683, Mycobac-
terium pheli NRRL B-8154 and mycobacterium fortuitum NRRL s-
8153. With the aid of these microorganisms, the fermentation
of c~-sitosterol can be carried out without using additional
agents for inhibiting the 9-hydroxylation.
Under the culture conditions conventionally used for
these microorganisms submerse cultures are grown in a suitable
nutrient medium while aerating. The substrate (dissolved in a
suitable solvent or preferably in the emulsified form) is then
added to the cultures and the fermentation is carried on until
a maximal conversion of the substrate is attained.
Suitable substrate solvents are, for example,
methanol, ethanol, glycol monomethyl ether, dimethyl formamide
or dimethyl sulphoxide. The emulsification of the substrate
can be carried out, for example, in that it is in;ected in a
micronized form or dissolved in solvent miscible with water
(such as methanol, ethanol, acetone, glycol monomethyl ether,
dimethyl formamide or dimethyl sulphoxide) with intense turbu-
lence in (preferably decalcified) water contalning the usual
emulsifying aids. Non-ionogenic emulsifiers, as for example,
ethyleneoxy adducts or fatty esters of polyglycols, are suit-
able emulsifying aids. The commercial wetting agents
Tegin(R), Tween(R) and Span(R) are examples of suitable emul-
sifiers.
The optimal substrate concentration, the time of
substrate addition and the fermentation time depend on the
structure of the substrate used on the type of microorganism

13029~3
used. AS generally required in microbiological steroid con-
versions these parameters must be determlned in the individual
case by preliminary tests with which the person skilled in the
art is familiar.
As is well known the 4-androstene-3,17-dione deriva-
tives having the general formula I and producible by means of
the process according to the present invention are valuable
intermediate products which are today used for the synthesis
of pharmacologically active steroids.
The process according to the present invention will
be illustrated by the following Examples.
Example l
A 2-litre Erlenmeyer flask with 500 ml of sterile
nutrient medium containing 1% of yeast extract, 0.45% of
disodium hydrogen phosphate, 0.34~ of potassium dihydrogen
phosphate and 0.2% of Tween(R)80 - adjusted to pH 6.7 - is
inoculated with a suspension of Mycobacterium spec. NRRL B-
3805 dry culture and shaken for 3 days at 30C with l9O revo-
lutions per minute.
Ten Erlenmeyer flasks (500 ml) each with 100 ml of
nutrient medium containing 2.5% of cornsteep liquor, 0.3% of
diammonium hydrogen phosphate, 0.25% of soybean mean and 0.25%
of Tween~R)80 - adjusted to p~ 7.0 - are inoculated with 5 ml
of Myobacterium spec. growth culture and shaken for 24 hours
at 30C with 220 revolutions per minute, whereupon 100 mg of
~ -sitosterol dissolved in 3.0 ml of dimethyl formamide are
added to each culture. The fermentation is then carried on
for further 96 hours at 30C.
The combined cultures are extracted with ethylene
chloride, the extract is concentrated in vacuo and the residue
is chromatographed via a silica gel column. On recrystalliz-
ing from diisopropyl ether 160 mg of 4-androstene-3,l7-dione

1302923
are obtained.
In addltion 385 mg of non-reacted ~-sitosterol are
recovered.
Example 2
Under the conditions of Example 1 but using
Mycobecterium spec. NRRL B-3683 a total of 1000 mg of ~-
sitosterol is reacted and further treated. 140 mg of 1~4-
androstadiene-3,17-dione are obtained in addition to 630 mg of
non-reacted q-sitosterol.

Representative Drawing

Sorry, the representative drawing for patent document number 1302923 was not found.

Administrative Status

2024-08-01:As part of the Next Generation Patents (NGP) transition, the Canadian Patents Database (CPD) now contains a more detailed Event History, which replicates the Event Log of our new back-office solution.

Please note that "Inactive:" events refers to events no longer in use in our new back-office solution.

For a clearer understanding of the status of the application/patent presented on this page, the site Disclaimer , as well as the definitions for Patent , Event History , Maintenance Fee  and Payment History  should be consulted.

Event History

Description Date
Inactive: IPC from MCD 2006-03-11
Time Limit for Reversal Expired 2005-06-09
Letter Sent 2004-06-09
Grant by Issuance 1992-06-09

Abandonment History

There is no abandonment history.

Fee History

Fee Type Anniversary Year Due Date Paid Date
MF (category 1, 6th anniv.) - standard 1998-06-09 1998-05-11
MF (category 1, 7th anniv.) - standard 1999-06-09 1999-05-12
MF (category 1, 8th anniv.) - standard 2000-06-09 2000-05-15
MF (category 1, 9th anniv.) - standard 2001-06-11 2001-05-16
MF (category 1, 10th anniv.) - standard 2002-06-10 2002-05-15
MF (category 1, 11th anniv.) - standard 2003-06-09 2003-05-14
Owners on Record

Note: Records showing the ownership history in alphabetical order.

Current Owners on Record
SCHERING AKTIENGESELLSCHAFT
Past Owners on Record
ALFRED WEBER
JOHANNES KURZIDIM
MARIO KENNECKE
Past Owners that do not appear in the "Owners on Record" listing will appear in other documentation within the application.
Documents

To view selected files, please enter reCAPTCHA code :



To view images, click a link in the Document Description column. To download the documents, select one or more checkboxes in the first column and then click the "Download Selected in PDF format (Zip Archive)" or the "Download Selected as Single PDF" button.

List of published and non-published patent-specific documents on the CPD .

If you have any difficulty accessing content, you can call the Client Service Centre at 1-866-997-1936 or send them an e-mail at CIPO Client Service Centre.


Document
Description 
Date
(yyyy-mm-dd) 
Number of pages   Size of Image (KB) 
Claims 1993-10-30 1 27
Abstract 1993-10-30 1 11
Drawings 1993-10-30 1 7
Descriptions 1993-10-30 5 162
Maintenance Fee Notice 2004-08-03 1 172
Fees 1997-05-13 1 172
Fees 1996-05-12 1 64
Fees 1994-05-15 1 205
Fees 1995-05-10 1 60